中文名称 |
Asiaticoside.
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
中文别名 |
积雪草苷;亚细亚皂苷;积雪草(积雪);1-金刚烷甲酮;积雪草苷 USP标准品;积雪草苷(标准品);积雪草苷 植物提取物,标准品,对照品;积雪草酸;积雪草皂苷(P);积雪草皂苷(RG);积雪草皂苷(SH);积雪草总苷;积草雪苷;积雪草单甙;积雪草甙;积雪草苷 标准品;积血草苷;积雪草粉;积雪草皂苷;积雪草甙异名;积雪草总苷(积雪草提取物);积雪草苷 20MG
|
||||||||||||
英文名称 |
Asiaticoside
|
||||||||||||
英文别名 |
asiaticoside;(O-alpha-L-Rhamnopyranoxyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl)-2alpha,3beta,23-trihydroxy-12-ursen-28-oat;2alpha,3beta,23-Trihydroxy-urs-12-en-28-saeure(O-alpha-L-rhamnopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl)ester;Asiaticosid;BRN 0078195;Ba 2742;Blastoestimulina;CCRIS 8995;Centelase;Dermatologico;Emdecassol;Madecassol;NSC 166062;O-6-Desoxy-alpha-L-mannopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-O-beta-D-glucopyranosyl 2alpha,3beta,23-trihydroxy-12-ursen-28-at;O-6-Deoxy-alpha-L-mannopyranosyl-(1.4)-O-beta-D-glucopyranosyl-(1.6)-beta-D-glucopyranosyl (2alpha,3beta,4alpha)-2,3,23-trihydroxyurs-12-en-28-oate;Urs-12-en-28-oic acid, 2,3,23-trihydroxy-, O-6-deoxy-alpha-L-mannopyranosyl-(1-4)-O-beta-D-glucopyranosyl-(1-6)-beta-D-glucopyranosyl ester, (2alpha,3beta,4alpha)-;Urs-12-en-28-oic acid, 2-alpha,3-beta,23-trihydroxy-, O-6-deoxy-alpha-L-mannopyranosyl-(1-4)-o-beta-D-glucopyranosyl-(1-6)-o-beta-D-glucopyranosyl ester;4)hexopyranosyl-(1->6)-1-O-(2,3,23-trihydroxy-28-oxours-12-en-28-yl)hexopyranose;Gotu Kola Extract;ASIATICOSIDE(P) PrintBack;Asiaticoside, froM Centella asiatica;Ba-2742;EMdesol;MADEOL;MADESOL;Martisol;scheffursoside F;[6-[[3,4-Dihydroxy-6-(hydroxymethyl)-5-(3,4,5-trihydroxy-6-methyl-oxan-2-yl)oxy-oxan-2-yl]oxymethyl]-3,4,5-trihydroxy-oxan-2-yl] (1S,2R,4aS,6aS,6bR,9S,10R,11R,12aS,14bR)-10,11-dihydroxy-9-(hydroxymeth;[6-[[3,4-Dihydroxy-6-(hydroxymethyl)-5-(3,4,5-trihydroxy-6-methyl-oxan-2-yl)oxy-oxan-2-yl]oxymethyl]-3,4,5-trihydroxy-oxan-2-yl] (1S,2R,4aS,6aS,6bR,9S,10R,11R,12aS,14bR)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylate;MADECASOL;Meal snow;Marticassol;N1357;[(2S,3R,4R,5R,6S)-6-[[(2R,3R,4S,5R,6S)-3,4-Dihydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5R,6S)-3,4,5-tri
|
||||||||||||
Cas No. |
16830-15-2
|
||||||||||||
分子式 |
C48H78O19
|
||||||||||||
分子量 |
959.12
|
||||||||||||
包装储存 |
|
生物活性 |
Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
性状 |
Solid |
||||||||||||
IC50 & Target[1][2] |
|
||||||||||||
体外研究(In Vitro) |
Asiaticoside (0, 100, 250, and 500 mg/L) dose-dependently inhibits keloid fibroblasts proliferation. Asiaticoside (100, 250, and 500 mg/L) decreases the expression of collagen protein and mRNA, reduces the expression of TGF-bRI, TGF-bRII protein, and mRNA, increases the expression of Smad7, but does not affect Smad2, Smad3, Smad4, phosphorylated Smad2, and phosphorylated Smad3 in keloid fibroblasts. Asiaticoside (12.5 and 50, and 25 and 50 μg/mL) prevents endothelial cells from hypoxia-induced inhibition of cell viability and NO production. Asiaticoside (50 μg/mL) also protects endothelial cells from hypoxia-induced apoptosis and upregulates and phosphorylation of AKT/eNOS in hypoxia-exposed HPAECs. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
体内研究(In Vivo) |
Asiaticoside (50 mg/kg daily) blocks the development of hypoxic pulmonary hypertension (PH), cardiovascular remodeling and endothelial cell injury in rats with pulmonary hypertension. Asiaticoside (5, 15 or 45 mg/kg, p.o.) improves the learning and memory deficit, protects hippocampi against the impairment, decreases Aβ deposits in the hippocampus, and ameliorates impaired subcellular structure in rats treated with Aβ oligomers. Medlife has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
运输条件 |
Room temperature or refrigerated transportation. |
||||||||||||
储存方式 |
|
||||||||||||
结构分类 | |||||||||||||
来源 | |||||||||||||
参考文献 |
|
溶解度数据 |
体外研究:
DMSO : 50 mg/mL (52.13 mM; Need ultrasonic) 配制储备溶液
*
产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效。 体内研究:
建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*
|
---|
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料,如有违反,将追究法律责任。
沪ICP备2023012080号 |
沪公网安备31011402010657号